Target intelligence / Profile preview

T cell receptor alpha variable 25 (TRAV25)

Target
TRAV25
Molecular classification
Receptor, Immunoglobulin superfamily, T cell receptor variable region
01

Overview

T cell receptor alpha variable 25 (TRAV25) is a segment of the alpha variable region of the T cell receptor (TCR) alpha chain. TCRs are heterodimeric membrane proteins found on T lymphocytes, crucial for antigen recognition as part of the adaptive immune response. The variable regions, including TRAV25, are generated by recombination of V (variable) and J (joining) gene segments during T cell development, allowing for the wide diversity of antigen recognition. The alpha-beta TCR recognizes peptide-MHC complexes displayed by antigen-presenting cells, initiating the signaling cascade required for T cell activation and immune defense. TRAV25 is not a full receptor on its own but rather one of many variable segments that, when combined in mature TCRs, provide the specificity needed for immune surveillance and response. In clinical research, engineering TCRs (using specific variable regions such as TRAV25) is explored for adoptive T cell transfer therapies in cancer and infectious disease contexts[1][3].

Other names
TCRAV25S1TCRAV32S1TRAV25T cell receptor alpha variable 25TVA25 protein
02

Mechanism of action

Targeting is generally through *adoptive T cell transfer* (engineered TCRs), where the mechanism involves antigen recognition presented on MHC complexes, leading to T cell activation and immune effector responses[3].

03

Biological functions

Antigen recognitionSignal transductionImmune responseT cell activationAdaptive immunity
04

Disease associations

Cancer (via engineered T cell receptor therapies)[3]Infection (in antigen-specific immune responses)[1]Inflammation
05

Safety considerations

Potential for mispairing of introduced TCR chains leading to off-target effects or autoimmunity[3]Loss of antigen specificity if engineered for super-physiological affinity[3]Risk of cytokine release syndrome in adoptive cell therapy settings
06

Interacting drugs

No specific drugs are known to interact directly with TRAV25; however, engineered T cell receptors containing TRAV25's variable region may be used in adoptive cell therapies targeting cancer antigens[3].
07

Biomarkers

Expression and sequence variants of TRAV25 may serve as biomarkers for T cell clonal expansion or T cell repertoire diversity, though not established specifically as clinical biomarkers[3]

Beyond the preview

Go deeper on T cell receptor alpha variable 25 (TRAV25).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor alpha variable 25 (TRAV25).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call